Auto-immune therapy against human allergic disease: a physiological self defence factor.
Guinea-pigs sensitised to ovalbumen excrete the antigen in their urine in a therapeutic concentration which prevents anaphylactic death after injection of a challenge dose of the ovalbumen. Sublingual administration of the correct dose of urine from allergic patients also provides therapeutic control of their allergic symptoms. The effective dose is determined by bio-assay. The Neutralisation dose is recognised by disappearance of buccal sensation to the urine. Readministration of salivary, nasal, and sweat secretions from allergic patients onto the conjunctiva also controls allergic symptoms. These procedures provide effective physiological self-defence therapies against allergic challenge in humans.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000652:urine*; D002648:Child; D002675:Child, Preschool; D003888:Desensitization, Immunologic / Q000379:methods*; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000378:metabolism; D010047:Ovalbumin / Q000494:pharmacology; D012463:Saliva / Q000276:immunology; D013542:Sweat / Q000276:immunology; D014556:Urine / Q000276:immunology
D000941:Antigens; D010047:Ovalbumin